Business Context and Reporting Period
This Form 8-K reports on the annual meeting of stockholders held by Oric Pharmaceuticals, Inc. on June 12, 2024. The filing details the voting results for director elections and the ratification of the independent registered public accounting firm.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document focuses exclusively on corporate governance voting outcomes.
Material Changes and Voting Results
Shareholder Participation: Of 67,422,307 shares outstanding as of the April 17, 2024 record date, 55,977,110 shares (83.02%) were represented at the meeting.
Proposal 1: Election of Directors
Two Class I directors were elected to serve until the 2027 annual meeting:
- Richard Heyman, Ph.D.: 36,581,862 votes For; 11,942,627 votes Withheld; 7,452,621 Broker Non-Votes.
- Lori Kunkel, M.D.: 48,020,921 votes For; 509,099 votes Withheld; 7,447,090 Broker Non-Votes.
Proposal 2: Ratification of Auditors
Stockholders ratified the appointment of KPMG LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024.
- For: 55,632,738
- Against: 6,150
- Abstain: 338,222
- Broker Non-Votes: 0
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Investor Verification Checklist
- Verify the tenure of the newly elected Class I directors (Richard Heyman and Lori Kunkel) through the 2027 annual meeting.
- Confirm KPMG LLP's engagement as the independent auditor for the fiscal year ending December 31, 2024.
- Note the significant number of broker non-votes (approx. 7.45 million) associated with the director election, which may indicate shares held in street name where brokers lacked discretionary voting power.